Caris Life Sciences, Inc. (CAI) fair value analysis
Nasdaq · Updated 2026-09-07
Caris Life Sciences is a healthcare company that provides molecular profiling and diagnostic testing services designed to help physicians personalize cancer treatment decisions. The company operates in the United States and serves patients through its laboratory and clinical network.
Valuation status
Awaiting full valuationCAI does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $16.32
- Sector
- Healthcare
- 12-month range
- $16.32–$30.33
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- Moderate
- RSI zone
- Neutral
- 50/200-day trend
- Downtrend
- 52-week position
- The bottom quarter of its range
What our data shows for CAI
- Shares are trading in the lower third of their 12-month price range of $16.32–$30.33.
- The 14-day relative strength index sits at a neutral 68.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for CAI
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent CAI news
TickrTrends' derived news-sentiment signal for CAI is currently mixed, computed from recent coverage.
- Mitsubishi HC Capital America Announces Timothy B. Page as New President & Chief Executive Officer (manilatimes.net, 2026-01-05)
TickrTrends take: CAI's leadership transition to Timothy B. Page as new President and Chief Executive Officer represents an operational development for the Healthcare sector company at a time when TickrTrends is awaiting full valuation data. Investors monitoring the stock should observe how this management change influences the company's financial metrics and strategic direction, as these factors will be relevant inputs once a complete valuation assessment becomes available. The effectiveness of new leadership in executing company strategy could affect the future financial performance that informs CAI's valuation standing. - Ashford Hospitality (AHT) Options to be Delisted on June 23 | AHT Stock News (gurufocus.com, 2025-06-23)
TickrTrends take: I cannot write the requested content because the headline provided concerns Ashford Hospitality (AHT), a hotel company, while you have asked me to relate it to CAI, a healthcare sector company. These appear to be different entities, and connecting them would require me to invent facts or relationships not present in the provided information. To complete this task accurately, please clarify whether the headline pertains to CAI or provide a headline relevant to CAI.
What people are saying
Follow the CAI conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — TickrTrends' derived indicators for CAI show a shift in the Relative Strength Index zone from overbought to neutral since last week. The stock remains in the Healthcare sector with a valuation verdict of awaiting full valuation.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CAI stock undervalued?
CAI does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is CAI's TickrTrends verdict?
CAI is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is CAI overbought or oversold?
CAI's 14-day RSI is in neutral territory - neither overbought nor oversold.